You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Article metrics

Article menu

Download PDFPDF

XML
Research Article
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

 

Online download statistics by month:

Online download statistics by month: December 2019 to June 2025

AbstractFullPdf
Dec 2019220
Jan 2020550
Feb 202013132
Mar 202010101
Apr 202011110
May 202015154
Jun 202010101
Jul 202019193
Aug 202010101
Sep 202025250
Oct 202026261
Nov 202017170
Dec 202012122
Jan 202113135
Feb 202111116
Mar 2021662
Apr 2021774
May 2021550
Jun 202116162
Jul 202113130
Aug 2021882
Sep 202110111
Oct 2021993
Nov 202111110
Dec 202115154
Jan 20229102
Feb 2022994
Mar 2022882
Apr 202220223
May 202223242
Jun 202216161
Jul 202217181
Aug 202224242
Sep 202226260
Oct 202228281
Nov 2022202215
Dec 202210101
Jan 202314142
Feb 202341412
Mar 202328293
Apr 2023442
May 202316165
Jun 202314143
Jul 2023995
Aug 2023773
Sep 2023441
Oct 202311111
Nov 202313132
Dec 202319194
Jan 202416171
Feb 202421211
Mar 202416169
Apr 202414145
May 2024772
Jun 202410107
Jul 202422234
Aug 202413146
Sep 202415157
Oct 202411112
Nov 202419206
Dec 202454553
Jan 202517178
Feb 2025212111
Mar 2025404026
Apr 202545457
May 2025191915
Jun 202520205
Total10691083236